{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T07:38:56Z","timestamp":1791617936051,"version":"4.3.4"},"reference-count":59,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["amjmedsci.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of the Medical Sciences"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.amjms.2025.12.781","type":"journal-article","created":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T16:06:42Z","timestamp":1765901202000},"page":"372-382","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Procalcitonin-driven pneumonia management\u2014are European and US antibiotic stewardship outcomes really different?"],"prefix":"10.1016","volume":"371","author":[{"given":"Doris","family":"Obimba","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Shaykevich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle R.","family":"Vitale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher A.","family":"Rudmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivayla I.","family":"Geneva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.amjms.2025.12.781_bib0001","doi-asserted-by":"crossref","DOI":"10.1186\/s13052-020-0770-3","article-title":"Blood biomarkers differentiating viral versus bacterial pneumonia aetiology: a literature review","volume":"46","author":"Thomas","year":"2020","journal-title":"Ital J Pediatr"},{"issue":"3","key":"10.1016\/j.amjms.2025.12.781_bib0002","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.2007","article-title":"Assessment of the appropriateness of antimicrobial use in US hospitals","volume":"4","author":"Magill","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"629","key":"10.1016\/j.amjms.2025.12.781_bib0003","doi-asserted-by":"crossref","first-page":"604","DOI":"10.3399\/bjgp14X682561","article-title":"Antibiotic overuse: a key driver of antimicrobial resistance","volume":"64","author":"Shallcross","year":"2014","journal-title":"Br J Gen Pract"},{"issue":"8","key":"10.1016\/j.amjms.2025.12.781_bib0004","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20082004","article-title":"Biomarkers in pneumonia\u2014Beyond procalcitonin","volume":"20","author":"Karakioulaki","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.amjms.2025.12.781_bib0005","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.613422","article-title":"Interleukin-6 is a biomarker for the development of fatal severe acute Respiratory syndrome coronavirus 2 pneumonia","volume":"12","author":"Santa Cruz","year":"2021","journal-title":"Front Immunol"},{"issue":"7","key":"10.1016\/j.amjms.2025.12.781_bib0006","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1097\/00006454-200007000-00003","article-title":"Serum procalcitonin, C-reactive protein and interleukin-6 for distinguishing bacterial and viral pneumonia in children","volume":"19","author":"Toikka","year":"2000","journal-title":"Pediatr Infect Dis J"},{"issue":"1","key":"10.1016\/j.amjms.2025.12.781_bib0007","doi-asserted-by":"crossref","DOI":"10.1186\/s40560-017-0246-8","article-title":"Procalcitonin: a promising diagnostic marker for sepsis and antibiotic therapy","volume":"5","author":"Vijayan","year":"2017","journal-title":"J Intensive Care"},{"issue":"12","key":"10.1016\/j.amjms.2025.12.781_bib0008","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0114710","article-title":"Predictors of viral pneumonia in patients with community-acquired pneumonia","volume":"9","author":"Kim","year":"2014","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.amjms.2025.12.781_bib0009","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1055\/s-0039-1696689","article-title":"Biomarkers of infection: are they useful in the ICU?","volume":"40","author":"Heilmann","year":"2019","journal-title":"Semin Respir Crit Care Med"},{"issue":"10","key":"10.1016\/j.amjms.2025.12.781_bib0010","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1128\/JCM.00382-15","article-title":"Point-counterpoint: large multiplex PCR panels should Be first-line tests for detection of Respiratory and intestinal pathogens","volume":"53","author":"Schreckenberger","year":"2015","journal-title":"J Clin Microbiol"},{"issue":"5","key":"10.1016\/j.amjms.2025.12.781_bib0011","first-page":"1011","article-title":"The role of multiplex PCR test in identification of bacterial pathogens in lower respiratory tract infections","volume":"30","author":"Aydemir","year":"2014","journal-title":"Pak J Med Sci"},{"issue":"7","key":"10.1016\/j.amjms.2025.12.781_bib0012","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.1128\/JCM.38.7.2763-2765.2000","article-title":"Evaluation of the Binax and Biotest urinary antigen kits for detection of Legionnaires' disease due to multiple serogroups and species of Legionella","volume":"38","author":"Benson","year":"2000","journal-title":"J Clin Microbiol"},{"issue":"5","key":"10.1016\/j.amjms.2025.12.781_bib0013","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1210\/endo-70-5-638","article-title":"Evidence for calcitonin\u2014A new hormone from the parathyroid that lowers blood calcium","volume":"70","author":"Copp","year":"1962","journal-title":"Endocrinology"},{"issue":"4813","key":"10.1016\/j.amjms.2025.12.781_bib0014","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/193381a0","article-title":"Calcitonin\u2014A hormone from the parathyroid which lowers the calcium-level of the blood","volume":"193","author":"Copp","year":"1962","journal-title":"Nature"},{"issue":"8844","key":"10.1016\/j.amjms.2025.12.781_bib0015","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/0140-6736(93)90277-N","article-title":"High serum procalcitonin concentrations in patients with sepsis and infection","volume":"341","author":"Assicot","year":"1993","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.amjms.2025.12.781_bib0016","first-page":"59","article-title":"Clinical utility and measurement of procalcitonin","volume":"38","author":"Samsudin","year":"2017","journal-title":"Clin Biochem Rev"},{"issue":"1","key":"10.1016\/j.amjms.2025.12.781_bib0017","doi-asserted-by":"crossref","DOI":"10.1186\/1741-7015-9-107","article-title":"Procalcitonin for diagnosis of infection and guide to antibiotic decisions: past, present and future","volume":"9","author":"Schuetz","year":"2011","journal-title":"BMC Med"},{"issue":"12","key":"10.1016\/j.amjms.2025.12.781_bib0018","doi-asserted-by":"crossref","first-page":"5578","DOI":"10.1210\/en.2003-0854","article-title":"In Vitro and in vivo calcitonin I gene expression in parenchymal cells: a novel product of Human adipose tissue","volume":"144","author":"Linscheid","year":"2003","journal-title":"Endocrinology"},{"key":"10.1016\/j.amjms.2025.12.781_bib0019","unstructured":"FDA clears test to help manage antibiotic treatment for lower respiratory tract infections and sepsis. US Food & Drug Administration. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-clears-test-help-manage-antibiotic-treatment-lower-respiratory-tract-infections-and-sepsis."},{"issue":"1","key":"10.1016\/j.amjms.2025.12.781_bib0020","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-057169","article-title":"How defensive medicine is defined in European medical literature: a systematic review","volume":"12","author":"Baungaard","year":"2022","journal-title":"BMJ Open"},{"issue":"11","key":"10.1016\/j.amjms.2025.12.781_bib0021","doi-asserted-by":"crossref","first-page":"406","DOI":"10.12998\/wjcc.v6.i11.406","article-title":"Defensive medicine: it is time to finally slow down an epidemic","volume":"6","author":"Vento","year":"2018","journal-title":"World J Clin Cases"},{"key":"10.1016\/j.amjms.2025.12.781_bib0022","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jclinepi.2015.06.005","article-title":"ROBIS: a new tool to assess risk of bias in systematic reviews was developed","volume":"69","author":"Whiting","year":"2016","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.amjms.2025.12.781_bib0023","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.cyto.2018.07.019","article-title":"Interleukin-5, interleukin-6, interferon induced protein-10, procalcitonin and C-reactive protein among mechanically ventilated severe community-acquired viral and bacterial pneumonia patients","volume":"113","author":"Karhu","year":"2019","journal-title":"Cytokine"},{"issue":"11","key":"10.1016\/j.amjms.2025.12.781_bib0024","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/resp.14372","article-title":"Predictors and outcomes of respiratory bacterial coinfections in patients with COVID-19 admitted to hospital: an observational prospective study","volume":"27","author":"Tiseo","year":"2022","journal-title":"Respirology"},{"issue":"12","key":"10.1016\/j.amjms.2025.12.781_bib0025","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1373\/clinchem.2019.306787","article-title":"Clinical utility of procalcitonin in the diagnosis of pneumonia","volume":"65","author":"Wussler","year":"2019","journal-title":"Clin Chem"},{"key":"10.1016\/j.amjms.2025.12.781_bib0026","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.ijid.2022.03.003","article-title":"Bacterial co-infection at hospital admission in patients with COVID-19","volume":"118","author":"Moreno-Garc\u00eda","year":"2022","journal-title":"Int J Infect Dis"},{"issue":"8","key":"10.1016\/j.amjms.2025.12.781_bib0027","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1007\/s00134-023-07161-1","article-title":"Procalcitonin and C-reactive protein to rule out early bacterial coinfection in COVID-19 critically ill patients","volume":"49","author":"Galli","year":"2023","journal-title":"Intensive Care Med"},{"issue":"2","key":"10.1016\/j.amjms.2025.12.781_bib0028","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1007\/s12028-018-0623-8","article-title":"Diagnostic accuracy of procalcitonin for early aspiration pneumonia in critically ill patients with Coma: a prospective study","volume":"30","author":"Legriel","year":"2018","journal-title":"Neurocrit Care"},{"issue":"2","key":"10.1016\/j.amjms.2025.12.781_bib0029","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1093\/cid\/cix317","article-title":"Procalcitonin as a marker of etiology in adults hospitalized with community-acquired pneumonia","volume":"65","author":"Self","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.amjms.2025.12.781_bib0030","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0262342","article-title":"Baseline procalcitonin as a predictor of bacterial infection and clinical outcomes in COVID-19: a case-control study","volume":"17","author":"Atallah","year":"2022","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.amjms.2025.12.781_bib0031","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1017\/ice.2022.262","article-title":"Effects of procalcitonin on antimicrobial treatment decisions in patients with coronavirus disease 2019 (COVID-19)","volume":"44","author":"Conlon","year":"2022","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"5","key":"10.1016\/j.amjms.2025.12.781_bib0032","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1017\/ice.2021.175","article-title":"The role of procalcitonin results in antibiotic decision-making in coronavirus disease 2019 (COVID-19)","volume":"43","author":"Fabre","year":"2021","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"4","key":"10.1016\/j.amjms.2025.12.781_bib0033","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02167-20","article-title":"Limited utility of procalcitonin in identifying community-associated bacterial infections in patients presenting with coronavirus disease 2019","volume":"65","author":"May","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.amjms.2025.12.781_bib0034","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1186\/s12877-022-03658-4","article-title":"Procalcitonin to reduce exposure to antibiotics and individualise treatment in hospitalised old patients with pneumonia: a randomised study","volume":"22","author":"Gavazzi","year":"2022","journal-title":"BMC Geriatr"},{"issue":"4","key":"10.1016\/j.amjms.2025.12.781_bib0035","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1007\/s00134-018-5141-9","article-title":"Procalcitonin algorithm to guide initial antibiotic therapy in acute exacerbations of COPD admitted to the ICU: a randomized multicenter study","volume":"44","author":"Daubin","year":"2018","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.amjms.2025.12.781_bib0036","doi-asserted-by":"crossref","first-page":"n2132","DOI":"10.1136\/bmj.n2132","article-title":"Procalcitonin and lung ultrasonography point-of-care testing to determine antibiotic prescription in patients with lower respiratory tract infection in primary care: pragmatic cluster randomised trial","volume":"374","author":"Lhopitallier","year":"2021","journal-title":"Bmj"},{"issue":"4","key":"10.1016\/j.amjms.2025.12.781_bib0037","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0175634","article-title":"Procalcitonin for selecting the antibiotic regimen in outpatients with low-risk community-acquired pneumonia using a rapid point-of-care testing: a single-arm clinical trial","volume":"12","author":"Masia","year":"2017","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.amjms.2025.12.781_bib0038","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.cmi.2023.01.009","article-title":"Respiratory multiplex PCR and procalcitonin to reduce antibiotic exposure in severe SARS-CoV-2 pneumonia: a multicentre randomized controlled trial","volume":"29","author":"Fartoukh","year":"2023","journal-title":"Clin Microbiol Infect"},{"issue":"1","key":"10.1016\/j.amjms.2025.12.781_bib0039","doi-asserted-by":"crossref","DOI":"10.1186\/s13613-021-00931-4","article-title":"Impact on antimicrobial consumption of procalcitonin-guided antibiotic therapy for pneumonia\/pneumonitis associated with aspiration in comatose mechanically ventilated patients: a multicenter, randomized controlled study","volume":"11","author":"Labro","year":"2021","journal-title":"Ann Intensive Care"},{"issue":"4","key":"10.1016\/j.amjms.2025.12.781_bib0040","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.annemergmed.2019.02.025","article-title":"Guideline-based clinical assessment versus procalcitonin-guided antibiotic use in pneumonia: a pragmatic randomized trial","volume":"74","author":"Montassier","year":"2019","journal-title":"Ann Emerg Med"},{"issue":"7","key":"10.1016\/j.amjms.2025.12.781_bib0041","doi-asserted-by":"crossref","DOI":"10.3390\/antibiotics12071208","article-title":"Compliance with a procalcitonin-based protocol in patients with ventilation-associated pneumonia: an observational, retrospective study","volume":"12","author":"Rossi","year":"2023","journal-title":"Antibiotics"},{"issue":"3","key":"10.1016\/j.amjms.2025.12.781_bib0042","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1177\/0018578719836643","article-title":"Impact of pharmacist-led procalcitonin-guided antibiotic therapy in critically ill patients with pneumonia","volume":"55","author":"Subedi","year":"2019","journal-title":"Hosp Pharm"},{"issue":"11","key":"10.1016\/j.amjms.2025.12.781_bib0043","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1093\/infdis\/jiv252","article-title":"Serum procalcitonin measurement and viral testing to guide antibiotic use for Respiratory infections in hospitalized adults: a randomized controlled trial. Randomized controlled trial research support, N.I.H., extramural research support, Non-U.S. Gov\u2019t","volume":"212","author":"Branche","year":"2015","journal-title":"J Infect Dis"},{"issue":"3","key":"10.1016\/j.amjms.2025.12.781_bib0044","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1056\/NEJMoa1802670","article-title":"Procalcitonin-guided use of antibiotics for lower Respiratory tract infection","volume":"379","author":"Huang","year":"2018","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.amjms.2025.12.781_bib0045","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofy327","article-title":"Procalcitonin-guided antibiotic therapy reduces antibiotic use for lower Respiratory tract infections in a United States medical center: results of a clinical trial","volume":"5","author":"Townsend","year":"2018","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"10.1016\/j.amjms.2025.12.781_bib0046","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/antibiotics2010001","article-title":"Efficacy and safety of procalcitonin-guided antibiotic therapy in lower Respiratory tract infections","volume":"2","author":"Drozdov","year":"2013","journal-title":"Antibiot (Basel)"},{"issue":"11","key":"10.1016\/j.amjms.2025.12.781_bib0047","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0163262","article-title":"Sensitivity and specificity of soluble triggering receptor expressed on myeloid cells-1, midregional proatrial natriuretic peptide and midregional proadrenomedullin for distinguishing etiology and to assess severity in community-acquired pneumonia","volume":"11","author":"Esposito","year":"2016","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.amjms.2025.12.781_bib0048","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1007\/s00431-017-2913-0","article-title":"A three-step diagnosis of pediatric pneumonia at the emergency department using clinical predictors, C-reactive protein, and pneumococcal PCR","volume":"176","author":"Alcoba","year":"2017","journal-title":"Eur J Pediatr"},{"issue":"8","key":"10.1016\/j.amjms.2025.12.781_bib0049","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0068419","article-title":"Procalcitonin guidance to reduce antibiotic treatment of lower respiratory tract infection in children and adolescents (ProPAED): a randomized controlled trial","volume":"8","author":"Baer","year":"2013","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.amjms.2025.12.781_bib0050","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1093\/jpids\/piw091","article-title":"Procalcitonin accurately identifies hospitalized children with low risk of bacterial community-acquired pneumonia","volume":"7","author":"Stockmann","year":"2018","journal-title":"J Pediatr Infect Dis Soc"},{"issue":"10","key":"10.1016\/j.amjms.2025.12.781_bib0051","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1097\/PEC.0000000000001259","article-title":"Procalcitonin levels in critically ill children with status Asthmaticus","volume":"35","author":"Samraj","year":"2019","journal-title":"Pediatr Emerg Care"},{"issue":"4","key":"10.1016\/j.amjms.2025.12.781_bib0052","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1542\/hpeds.2021-006510","article-title":"Association between procalcitonin and antibiotics in children with community-acquired pneumonia","volume":"12","author":"Sekmen","year":"2022","journal-title":"Hosp Pediatr"},{"key":"10.1016\/j.amjms.2025.12.781_bib0053","article-title":"The burden of antimicrobial resistance in the Americas in 2019: a cross-country systematic analysis","volume":"25","author":"Aguilar","year":"2023","journal-title":"Lancet Reg Health 13 Am"},{"issue":"6","key":"10.1016\/j.amjms.2025.12.781_bib0054","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1177\/2042098614554919","article-title":"Antimicrobial resistance: risk associated with antibiotic overuse and initiatives to reduce the problem","volume":"5","author":"Llor","year":"2014","journal-title":"Ther Adv Drug Saf"},{"issue":"3","key":"10.1016\/j.amjms.2025.12.781_bib0055","first-page":"195","article-title":"The effects of the COVID-19 pandemic on community respiratory virus activity","volume":"21","author":"Chow","year":"2023","journal-title":"Nat Rev Microbiol"},{"issue":"1","key":"10.1016\/j.amjms.2025.12.781_bib0056","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.cmi.2020.09.041","article-title":"Recommendations for antibacterial therapy in adults with COVID-19 - an evidence based guideline","volume":"27","author":"Sieswerda","year":"2021","journal-title":"Clin Microbiol Infect"},{"issue":"9","key":"10.1016\/j.amjms.2025.12.781_bib0057","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1515\/cclm-2018-1181","article-title":"Procalcitonin (PCT)-guided antibiotic stewardship: an international experts consensus on optimized clinical use","volume":"57","author":"Schuetz","year":"2019","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.amjms.2025.12.781_bib0058","author":"MZAa"},{"key":"10.1016\/j.amjms.2025.12.781_bib0059","first-page":"399","article-title":"A comparative law look at pain and suffering awards","volume":"55","author":"Sugarman","year":"2006","journal-title":"DePaul Law Rev"}],"container-title":["The American Journal of the Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002962925020816?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002962925020816?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T16:19:48Z","timestamp":1773418788000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002962925020816"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":59,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S0002962925020816"],"URL":"https:\/\/doi.org\/10.1016\/j.amjms.2025.12.781","relation":{},"ISSN":["0002-9629"],"issn-type":[{"value":"0002-9629","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Procalcitonin-driven pneumonia management\u2014are European and US antibiotic stewardship outcomes really different?","name":"articletitle","label":"Article Title"},{"value":"The American Journal of the Medical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjms.2025.12.781","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc. on behalf of Southern Society for Clinical Investigation.","name":"copyright","label":"Copyright"}]}}